Advertisement

Physical activity, exercise capacity and mortality risk in people with interstitial lung disease: A systematic review and meta-analysis

  • Vânia Rocha
    Correspondence
    Corresponding author.
    Affiliations
    Respiratory Research and Rehabilitation Laboratory (Lab3R), School of Health Sciences (ESSUA) and Institute of Biomedicine (iBiMED), University of Aveiro, Portugal
    Search for articles by this author
  • Cátia Paixão
    Affiliations
    Respiratory Research and Rehabilitation Laboratory (Lab3R), School of Health Sciences (ESSUA) and Institute of Biomedicine (iBiMED), University of Aveiro, Portugal

    Department of Medical Sciences, University of Aveiro, Portugal
    Search for articles by this author
  • Alda Marques
    Affiliations
    Respiratory Research and Rehabilitation Laboratory (Lab3R), School of Health Sciences (ESSUA) and Institute of Biomedicine (iBiMED), University of Aveiro, Portugal
    Search for articles by this author
Published:October 06, 2022DOI:https://doi.org/10.1016/j.jsams.2022.10.002

      Abstract

      Objectives

      Physical activity and exercise measures show potential to predict mortality in people with interstitial lung disease. This study summarized evidence on the association between physical activity and exercise capacity measures and mortality risk in people with interstitial lung disease and quantified its magnitude by meta-analysis.

      Design

      Systematic review and meta-analysis.

      Methods

      PubMed, Scopus, Web of Science and EBSCO were searched until May 2020 with updates until September 2021. Two authors screened studies, extracted data, and assessed risk of bias. A random-effects meta-analysis for each physical activity measure was conducted using logarithmic hazard ratios.

      Results

      Fifty-two studies of 10,349-people with interstitial lung disease (64 ± 9 years; 67%men) were included. A significant association between at least one measure of physical activity and exercise and mortality risk was found in 44-studies. Most reported measures were the six-minute walk test, oxygen uptake (VO2), work (watts-W) and time spent in physical activity. Meta-analysis showed that individuals with six-minute walk distance < 250 m had more than twofold higher mortality risk, than those with six-minute walk distance ≥ 350 m. Individuals presenting a six-minute walk distance decrease ≥ 26 m over 6–48 months showed an almost threefold higher mortality risk. An increase of 10–20 W or 10 %predicted in workload and a time spent in physical activity ≥ 100 min/week or ≥0.031 kcal/min/kg/day were associated with an overall 12 % and 45 % lower mortality risk, respectively.

      Conclusions

      Physical activity and exercise capacity measures were associated with mortality risk in people with interstitial lung disease. Most studies used the six-minute walk test and more evidence is needed on the other measures (i.e., VO2, work and physical activity time). Personalized interventions to improve physical activity and exercise capacity should be considered to delay premature mortality in people with interstitial lung disease.

      PROSPERO registration number

      CRD42020187952.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Science and Medicine in Sport
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Travis W.D.
        • et al.
        An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
        Am J Respir Crit Care Med. 2013; 188: 733-748https://doi.org/10.1164/rccm.201308-1483ST
        • Choi W.I.
        • Park S.H.
        • Dauti S.
        • et al.
        Interstitial lung disease and risk of mortality: 11-year nationwide population-based study.
        Int J Tuberc Lung Dis. 2018; 22: 100-105https://doi.org/10.5588/ijtld.17.0167
        • Pesonen I.
        • et al.
        Six-minute walking test outweighs other predictors of mortality in idiopathic pulmonary fibrosis. A real-life study from the Swedish IPF registry.
        Respir Med. 2020; 2https://doi.org/10.1016/j.yrmex.2020.100017
        • Alfaro T.M.
        • et al.
        Research highlights from the 2018 ERS International Congress: interstitial lung diseases.
        ERJ Open Res. 2019; 5: 00215-02018https://doi.org/10.1183/23120541.00215-2018
        • Karanth M.S.
        • Awad N.T.
        Six minute walk test: a tool for predicting mortality in chronic pulmonary diseases.
        J Clin Diagn Res. 2017; 11: OC34-OC38https://doi.org/10.7860/JCDR/2017/24707.9723
        • du Bois R.M.
        6-minute walk distance as a predictor of outcome in idiopathic pulmonary fibrosis.
        Eur Respir J. 2014; 43: 1823-1824https://doi.org/10.1183/09031936.00002514
        • Dowman L.
        • Hill C.J.
        • Holland A.E.
        Pulmonary rehabilitation for interstitial lung disease.
        Cochrane Database Syst Rev. 2014; https://doi.org/10.1002/14651858.CD006322.pub3
        • Nishiyama O.
        • et al.
        Physical activity in daily life in patients with idiopathic pulmonary fibrosis.
        Respir Investig. 2018; 56: 57-63https://doi.org/10.1016/j.resinv.2017.09.004
        • Flaherty K.R.
        • et al.
        Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test.
        Am J Respir Crit Care Med. 2006; 174: 803-809https://doi.org/10.1164/rccm.200604-488OC
        • Triantafillidou C.
        • et al.
        The role of cardiopulmonary exercise test in IPF prognosis.
        Pulm Med. 2013; https://doi.org/10.1155/2013/514817
        • Vainshelboim B.
        • Oliveira J.
        • Fox B.D.
        • et al.
        The prognostic role of ventilatory inefficiency and exercise capacity in idiopathic pulmonary fibrosis.
        Respir Care. 2016; 61: 1100-1109https://doi.org/10.4187/respcare.04471
        • Singh S.J.
        • et al.
        An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease.
        Eur Respir J. 2014; 44: 1447https://doi.org/10.1183/09031936.00150414
        • Brown A.W.
        • Nathan S.D.
        The value and application of the 6-minute-walk test in idiopathic pulmonary fibrosis.
        Ann Am Thorac Soc. 2017; 15: 3-10https://doi.org/10.1513/AnnalsATS.201703-244FR
        • Lancaster L.H.
        Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis.
        Multidiscip Respir Med. 2018; 13https://doi.org/10.1186/s40248-018-0158-z
        • World Health Organization, W
        Global action Plan on Physical Activity 2018–2030: More Active People for a Healthier World.
        2018 ([Geneva, Switzerland])
        • Wells G.A.
        • et al.
        The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
        • Alhamad E.
        • et al.
        Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis.
        Ann Thorac Med. 2020; 15: 208-214https://doi.org/10.4103/atm.ATM_230_20
        • Du Bois R.M.
        • et al.
        Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.
        Am J Respir Crit Care Med. 2011; 183: 1231-1237https://doi.org/10.1164/rccm.201007-1179OC
        • Kawut S.M.
        • et al.
        Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation.
        Respir Med. 2005; 99: 1431-1439https://doi.org/10.1016/j.rmed.2005.03.007
        • Salinas M.
        • et al.
        Survival of patients with biopsy-proven idiopathic pulmonary fibrosis: Chilean National Thorax Institute experience.
        Rev Med Chil. 2014; 142: 9-15https://doi.org/10.4067/S0034-98872014000100002
        • King Jr., T.E.
        • Tooze J.A.
        • Schwarz M.I.
        • et al.
        Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.
        Am J Respir Crit Care Med. 2001; 164: 1171-1181https://doi.org/10.1164/ajrccm.164.7.2003140
        • Gao J.
        • et al.
        Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry.
        Respir Res. 2021; 22: 40https://doi.org/10.1186/s12931-021-01634-x
        • Du Bois R.M.
        • et al.
        6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.
        Eur Respir J. 2014; 43: 1421-1429https://doi.org/10.1183/09031936.00131813
        • Fell C.D.
        • et al.
        The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.
        Am J Respir Crit Care Med. 2009; 179: 402-407https://doi.org/10.1164/rccm.200802-241OC
        • Hallstrand T.S.
        • et al.
        The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis.
        Eur Respir J. 2005; 25: 96-103https://doi.org/10.1183/09031936.04.00137203
        • Hsu V.M.
        • et al.
        Risk factors for mortality and cardiopulmonary hospitalization in systemic sclerosis patients at risk for pulmonary hypertension, in the pharos registry.
        J Rheumatol. 2019; 46: 176-183https://doi.org/10.3899/jrheum.180018
        • Lama V.N.
        • et al.
        Prognostic value of desaturation during a 6 minute walk test in idiopathic interstitial pneumonia.
        Am J Respir Crit Care Med. 2003; 168: 1084-1090https://doi.org/10.1164/rccm.200302-219OC
        • Layton A.M.
        • et al.
        Cardiopulmonary exercise factors predict survival in patients with advanced interstitial lung disease referred for lung transplantation.
        Respir Med. 2017; 126: 59-67https://doi.org/10.1016/j.rmed.2017.03.022
        • Lederer D.J.
        • et al.
        Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis.
        Am J Respir Crit Care Med. 2006; 174: 659-664https://doi.org/10.1164/rccm.200604-520OC
        • Ley B.
        • et al.
        Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis.
        Am J Respir Crit Care Med. 2016; 194: 711-718https://doi.org/10.1164/rccm.201508-1546OC
        • Nathan S.D.
        • et al.
        Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.
        Respir Med. 2015; 109: 914-922https://doi.org/10.1016/j.rmed.2015.04.008
        • Swigris J.J.
        Exercise peripheral oxygen saturation (Spo2) accurately reflects arterial oxygen saturation (Sao2) and predicts mortality in systemic sclerosis.
        Thorax. 2009; 64: 626-630https://doi.org/10.1136/thx.2008.111393
        • Furukawa T.
        • et al.
        The St. George's Respiratory Questionnaire as a prognostic factor in IPF.
        Respir Res. 2017; 18https://doi.org/10.1186/s12931-017-0503-3
        • Ikezoe K.
        • et al.
        Prognostic factors and outcomes in Japanese lung transplant candidates with interstitial lung disease.
        PLoS One. 2017; 12https://doi.org/10.1371/journal.pone.0183171
        • Miki K.
        • et al.
        Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis.
        Respir Med. 2003; 97: 482-490https://doi.org/10.1053/rmed.2002.1469
        • Nishiyama O.
        • et al.
        A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis.
        Eur Respir J. 2010; 36: 1067-1072https://doi.org/10.1183/09031936.00152609
        • Nishiyama O.
        • et al.
        Fat-free mass index predicts survival in patients with idiopathic pulmonary fibrosis.
        Respirology. 2017; 22: 480-485https://doi.org/10.1111/resp.12941
        • Oshima A.
        • et al.
        Nutrition-related factors associated with waiting list mortality in patients with interstitial lung disease: a retrospective cohort study.
        Clin Transpl. 2019; 33https://doi.org/10.1111/ctr.13566
        • Sokai A.
        • et al.
        The association between health-related quality of life and disease progression in idiopathic pulmonary fibrosis: a prospective cohort study.
        Sarcoidosis Vasc Diffuse Lung Dis. 2017; 34: 226-235
        • Shitrit D.
        • et al.
        The 15-step oximetry test: a reliable tool to identify candidates for lung transplantation among patients with idiopathic pulmonary fibrosis.
        J Heart Lung Transplant. 2009; 28: 328-333https://doi.org/10.1016/j.healun.2008.12.019
        • Vainshelboim B.
        • Kramer M.R.
        • Izhakian S.
        • et al.
        Physical activity and exertional desaturation are associated with mortality in idiopathic pulmonary fibrosis.
        J Clin Med. 2016; 5https://doi.org/10.3390/jcm5080073
        • Vainshelboim B.
        • et al.
        8-Foot-Up-and-Go Test is associated with hospitalizations and mortality in idiopathic pulmonary fibrosis: a prospective pilot study.
        Lung. 2019; 197: 81-88https://doi.org/10.1007/s00408-018-0189-4
        • Vainshelboim B.
        • et al.
        Physiological responses and prognostic value of common exercise testing modalities in idiopathic pulmonary fibrosis.
        J Cardiopulm Rehabil Prev. 2018; https://doi.org/10.1097/hcr.0000000000000362
        • Vainshelboim B.
        • Oliveira J.
        • Izhakian S.
        • et al.
        Lifestyle behaviors and clinical outcomes in idiopathic pulmonary fibrosis.
        Respiration. 2018; 95: 27-34https://doi.org/10.1159/000481202
        • Alhamad E.
        • Cal J.
        Predictors of mortality in interstitial lung disease patients without pulmonary hypertension.
        Ann Thorac Med. 2020; 15: 238-243https://doi.org/10.4103/atm.ATM_438_20
        • Bahmer T.
        • et al.
        Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.
        BMC Pulm Med. 2017; 17https://doi.org/10.1186/s12890-017-0444-0
        • Caminati A.
        • Bianchi A.
        • Cassandro R.
        • et al.
        Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis.
        Respir Med. 2009; 103: 117-123https://doi.org/10.1016/j.rmed.2008.07.022
        • Chan C.
        • Ryerson C.J.
        • Dunne J.V.
        • et al.
        Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study.
        BMC Pulm Med. 2019; 19https://doi.org/10.1186/s12890-019-0943-2
        • Jo H.E.
        • et al.
        Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.
        BMC Pulm Med. 2018; 18https://doi.org/10.1186/s12890-018-0575-y
        • Lee S.M.
        • et al.
        Prediction of survival by texture-based automated quantitative assessment of regional disease patterns on CT in idiopathic pulmonary fibrosis.
        Eur Radiol. 2018; 28: 1293-1300https://doi.org/10.1007/s00330-017-5028-0
        • Lee J.H.
        • Chae E.J.
        • Song J.S.
        • et al.
        Pleuroparenchymal fibroelastosis in Korean patients: clinico-radiologic-pathologic features and 2-year follow-up.
        Korean J Intern Med. 2020; https://doi.org/10.3904/kjim.2019.303
        • Mura M.
        • et al.
        Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study.
        Eur Respir J. 2012; 40: 101-109https://doi.org/10.1183/09031936.00106011
        • Perez J.J.B.
        • et al.
        The 6-minute walk test as a tool for determining exercise capacity and prognosis in patients with silicosis.
        Archivos De Bronconeumologia. 2019; 55: 88-92https://doi.org/10.1016/j.arbres.2018.07.004
        • Ryerson C.J.
        • et al.
        Predicting mortality in systemic sclerosis-associated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis.
        Chest. 2015; 148: 1268-1275https://doi.org/10.1378/chest.15-0003
        • Serajeddini H.
        • Rogliani P.
        • Mura M.
        Multi-dimensional assessment of IPF across a wide range of disease severity.
        Lung. 2018; 196: 707-713https://doi.org/10.1007/s00408-018-0152-4
        • Song J.W.
        • et al.
        Blood biomarkers MMP-7 and SP-A predictors of outcome in idiopathic pulmonary fibrosis.
        Chest. 2013; 143: 1422-1429https://doi.org/10.1378/chest.11-2735
        • Swigris J.J.
        • et al.
        Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis.
        Chest. 2009; 136: 841-848https://doi.org/10.1378/chest.09-0211
        • Guler S.A.
        • et al.
        Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study.
        Thorax. 2021; ([thoraxjnl-2021-217361])https://doi.org/10.1136/thoraxjnl-2021-217361
        • Mancuzo E.V.
        • Soares M.R.
        • Pereira C.A.C.
        Six-minute walk distance and survival time in patients with idiopathic pulmonary fibrosis in Brazil.
        J Bras Pneumol. 2018; 44: 267-272https://doi.org/10.1590/s1806-37562018000000049
        • Barratt S.L.
        • Davis R.
        • Sharp C.
        • et al.
        The prognostic value of cardiopulmonary exercise testing in interstitial lung disease: a systematic review.
        ERJ Open Res. 2020; 6: 00027-02020https://doi.org/10.1183/23120541.00027-2020
        • Dowman L.
        • Hill C.J.
        • May A.
        • et al.
        Pulmonary rehabilitation for interstitial lung disease.
        Cochrane Database Syst Rev. 2021; https://doi.org/10.1002/14651858.CD006322.pub4
        • Page M.J.
        • McKenzie J.E.
        • Bossuyt P.M.
        • et al.
        The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
        Syst Rev. 2021; 10: 89https://doi.org/10.1186/s13643-021-01626-4